HB 916

PRIOR PRINTER'S NO. 965  PRINTER'S NO.   3286
                THE GENERAL ASSEMBLY OF PENNSYLVANIA
                    HOUSE BILL
                    No. 916
                                           Session of
                                             2025
INTRODUCED BY GIRAL, PIELLI, SANCHEZ, McNEILL, HILL-EVANS,
   SCHLOSSBERG, HOHENSTEIN, CIRESI, OTTEN, WEBSTER, GREEN AND
   RIVERA, MARCH 17, 2025
AS REPORTED FROM COMMITTEE ON HEALTH, HOUSE OF REPRESENTATIVES,
   AS AMENDED, APRIL 28, 2026
                               AN ACT
1 Amending the act of November 3, 2022 (P.L.2135, No.150),  <--
2    entitled "An act providing for blood lead assessment and
3    testing of certain children and pregnant women by health care
4    providers; imposing duties on the Department of Health; and
5    requiring certain health insurance policies to cover blood
6    lead tests," further providing for legislative findings and
7    for definitions; repealing provisions relating to lead
8    poisoning prevention, assessment and testing; providing for
9    lead poisoning prevention, assessment and testing; and
10    further providing for duties of department and for blood lead
11    assessment and testing coverage.
12    The General Assembly of the Commonwealth of Pennsylvania
13 hereby enacts as follows:
14    Section 1.    Section 2 of the act of November 3, 2022
15 (P.L.2135, No.150), known as the Childhood Blood Lead Test Act,
16 is amended by adding paragraphs to read:
17 Section 2.   Legislative findings.
18    The General Assembly finds that:
19* * *
20(8)   No safe blood lead level in children has been
21    identified.
1(9)    The effects of lead poisoning are not reversible.
2    Section 2.    Section 4 of the act is amended by adding
3 definitions to read:
4 Section 4.    Definitions.
5    The following words and phrases when used in this act shall
6 have the meanings given to them in this section unless the
7 context clearly indicates otherwise:
8    "Birthing facility."      An inpatient or ambulatory health care
9 facility licensed by the department that provides birthing and
10 newborn care services.
11    "Blood lead level."       A measure of lead in the blood, measured
12 in micrograms of lead per deciliter of whole blood (µg/dL).
13    * * *
14    "Child."    A child younger than 72 months of age who is a
15 resident of this Commonwealth.
16    * * *
17    "Diagnostic blood lead level testing."      An analysis of a
18 blood sample to determine blood lead levels for the sample,
19 which is obtained by venipuncture or capillary blood sampling
20 for the purpose of any of the following:
21(1)    Confirming lead poisoning as a follow-up blood lead
22    level test.
23(2)    Diagnosing a child or pregnant woman showing signs
24    or symptoms of lead poisoning.
25(3)    Diagnosing a child or pregnant woman suspected of
26    having sustained a significant lead exposure.
27    "Diagnostic evaluation."       Obtaining and evaluating medical
28 history information, conducting a physical examination and
29 diagnostic blood lead level testing, identifying potential
30 sources of lead exposure and evaluating iron status.
20250HB0916PN3286  - 2 -
1    * * *
2    "Lead poisoning."        A blood lead level that meets one of the
3 following criteria:
4(1)   A confirmed blood lead level greater than or equal
5    to 20 µg/dL in a child or pregnant woman.
6(2)   Two blood lead level samples of a child or pregnant
7    woman, separated by at least 90 days, but not more than 365
8    days, which indicate a blood lead level greater than or equal
9    to 15 µg/dL.
10    "Lead-screening-related services."        Any of the following:
11(1)   Materials and supplies used to obtain blood
12    specimens for quantitative blood lead level or erythrocyte
13    protoporphyrin analysis.
14(2)   Laboratory analysis of submitted samples for
15    quantitative blood lead level testing or erythrocyte
16    protoporphyrin analysis.
17(3)   Evaluation of results obtained from laboratory
18    analysis of samples submitted for quantitative blood lead
19    level or erythrocyte protoporphyrin analysis, as well as
20    related consultation, referral and follow-up of children and
21    pregnant women who potentially have lead poisoning.
22    "Screening test."       A blood sample obtained by venipuncture or
23 capillary blood sampling from an asymptomatic child or pregnant
24 woman not known to have lead poisoning to identify risk of lead
25 poisoning for the child or pregnant woman.
26    Section 3.        Section 5 of the act is repealed:
27 [Section 5.     Lead poisoning prevention, assessment and testing.
28    (a)   Lead testing for children.--
29(1)   The following apply:
30(i)    A health care provider shall consider possible
20250HB0916PN3286  - 3 -
1lead exposure in an individual patient by evaluating risk
2factors for lead exposure and perform blood lead testing
3in accordance with recommendations from the Centers for
4Disease Control and Prevention and the American Academy
5of Pediatrics by 24 months of age.
6(ii)    If a patient has never been tested in
7accordance with recommendations from the Centers for
8Disease Control and Prevention and the American Academy
9of Pediatrics by 24 months of age, a health care provider
10shall consider possible lead exposure and perform blood
11lead testing in an individual patient between 24 months
12and 72 months of age.
13(iii)    A health care provider shall make reasonable
14efforts to ensure that a patient's parent or legal
15guardian understands the risks and benefits of blood lead
16testing prior to obtaining consent.
17(2)   If a patient's parent or legal guardian consents to
18    blood lead testing for the patient under paragraph (1) and
19    the results of a capillary blood lead test indicate an
20    elevated blood lead level, the health care provider shall
21    perform a confirmatory blood lead test by venipuncture within
22    12 weeks of the first blood lead test after obtaining the
23    consent of the patient's parent or legal guardian.
24    (b)   Lead exposure risk assessment and testing requirements
25 for pregnant women.--A health care provider shall consider
26 possible lead exposure in individual pregnant women by
27 evaluating risk factors for lead exposure and perform blood lead
28 testing if a single risk factor is identified in accordance with
29 recommendations from the Centers for Disease Control and
30 Prevention and the American College of Obstetricians and
20250HB0916PN3286  - 4 -
1 Gynecologists.
2    (c)   Reporting.--Health care providers and laboratories shall
3 comply with reporting regulations as specified in 28 Pa. Code §
4 27.34 (relating to reporting cases of lead poisoning).]
5    Section 4.    The act is amended by adding a section to read:
6 Section 5.1.    Lead poisoning prevention, assessment and testing.
7    (a)   Lead testing requirements for children.--
8(1)   A health care provider or certified assistant of a
9    health care provider shall make reasonable efforts to ensure
10    that a child under the health care provider's care receives
11    at least one blood lead test by 24 months of age or between
12    the ages of 24 through 72 months of age if the child has
13    never been tested in accordance with recommendations from the
14    Centers for Disease Control and Prevention and the American
15    Academy of Pediatrics.
16(2)   If the results of a blood lead test under paragraph
17    (1) indicate an elevated blood lead level, the health care
18    provider or certified assistant of the health care provider
19    shall perform a confirmatory blood lead test on the child
20    within 12 weeks of the first blood lead test.
21(3)   A health care provider or certified assistant of a
22    health care provider shall perform a screening test for a
23    child under the health care provider's care who is designated
24    as high risk through a risk assessment evaluation promulgated
25    by the department on an annual basis from 12 months of age to
26    72 months of age.
27(4)   Upon recommendation by a health care provider, a
28    health care provider or certified assistant of a health care
29    provider may perform frequent screening tests on an
30    asymptomatic child under the health care provider's care who
20250HB0916PN3286  - 5 -
1    is younger than 72 months of age.
2    (b)   Lead testing requirements for pregnant women.--A health
3 care provider or certified assistant of a health care provider
4 shall make reasonable efforts to ensure that a pregnant woman
5 under the health care provider's care receives at least one
6 blood lead test as part of the pregnant woman's prenatal care.
7    (c)   Testing methods.--Health care providers shall ensure
8 that screening tests are conducted by venipuncture or capillary
9 blood sampling in accordance with regulations promulgated by the
10 department.
11    (d)   Reporting.--Health care providers and laboratories shall
12 comply with reporting regulations as specified in 28 Pa. Code §
13 27.34 (relating to reporting cases of lead poisoning).
14    (e)   Nonapplicability.--If a child's parent or legal guardian
15 or a pregnant woman receiving prenatal care objects in writing
16 to a blood lead test on religious grounds or on the basis of a
17 strong moral or ethical conviction similar to a religious
18 belief, a health care provider or certified assistant of the
19 health care provider shall perform a diagnostic evaluation in
20 the least invasive manner practicable.
21    Section 5.     Section 6(b)(1) of the act is amended, the
22 subsection is amended by adding paragraphs and the section is
23 amended by adding a subsection to read:
24 Section 6.     Duties of department.
25    * * *
26    (b)   Distribution of literature about childhood lead
27 poisoning.--
28(1)   The department shall provide culturally and
29    linguistically appropriate educational materials regarding
30    childhood lead poisoning, the risk factors associated with
20250HB0916PN3286  - 6 -
1    lead exposure, the importance of assessments and testing for
2    elevated lead levels, prevention of childhood lead poisoning,
3    treatment of childhood lead poisoning, remediation and, when
4    appropriate, the requirements of this act.
5* * *
6(3)   A hospital, birthing facility or health care
7    provider shall provide the information under subsection (a)
8    and the educational materials under this subsection without
9    cost to a parent of a newborn prior to discharge from the
10    hospital or birthing facility or, if childbirth occurs in a
11    setting other than a hospital or birthing facility, by a
12    health care provider who assists the parent during
13    childbirth.
14(4)   A parent of a newborn prior to discharge from a
15    hospital or birthing facility, or after a childbirth that
16    takes place in a setting other than a hospital or birthing
17    facility, shall sign an acknowledgment statement in a form
18    determined by the department that the parent received the
19    information under subsection (a) and the educational
20    materials under this subsection. A hospital, birthing
21    facility or health care provider shall provide a copy of the
22    acknowledgment statement to the parent and keep another copy
23    of the acknowledgment statement on file at the hospital,
24    birthing facility or setting other than a hospital or
25    birthing facility, as applicable.
26    (c)   Liability.--A hospital, birthing facility or health care
27 provider shall not be civilly or criminally liable for the
28 action or inaction of a parent with regard to lead exposure
29 based on the information under subsection (a) and the
30 educational materials under subsection (b).
20250HB0916PN3286  - 7 -
1    Section 6.     Section 7(a) of the act is amended and the
2 section is amended by adding subsections to read:
3 Section 7.     Blood lead assessment and testing coverage.
4    (a)   [General rule] Coverage.--A health insurance policy or
5 government program covered under this section shall provide to
6 covered individuals or recipients [blood lead tests as follows:
7(1)   In the case of individuals or recipients who are
8    pregnant, one blood lead test per pregnancy if a single risk
9    factor is identified in accordance with recommendations from
10    the Centers for Disease Control and Prevention and the
11    American College of Obstetricians and Gynecologists.
12(2)   In the case of individuals or recipients who are
13    under two years of age, at least one blood lead test by 24
14    months of age in accordance with recommendations from the
15    Centers for Disease Control and Prevention and the American
16    Academy of Pediatrics and, if the result of the blood level
17    test indicates an elevated blood lead level, another blood
18    lead test by venipuncture within 12 weeks of the blood level
19    test in which the elevated blood lead level was indicated.]
20    coverage for all of the following:
21(3)   Screening tests and lead-screening-related services
22    for children younger than 72 months of age and pregnant
23    women.
24(4)   Diagnostic evaluations.
25    (a.1)     Services.--The department shall provide the following
26 services for children younger than 72 months of age and pregnant
27 women who are not covered by a health insurance policy:
28(1)   Screening tests and lead-screening-related services.
29(2)   Diagnostic evaluations.
30    (a.2)     Reimbursement.--The department shall not be required
20250HB0916PN3286  - 8 -
1 to reimburse a third party for services under subsection (b)
2 that are not provided by the department.
3    * * *
4    Section 7. This act shall take effect in 60 days.
5 AMENDING THE ACT OF NOVEMBER 3, 2022 (P.L.2135, NO.150),  <--
6    ENTITLED "AN ACT PROVIDING FOR BLOOD LEAD ASSESSMENT AND
7    TESTING OF CERTAIN CHILDREN AND PREGNANT WOMEN BY HEALTH CARE
8    PROVIDERS; IMPOSING DUTIES ON THE DEPARTMENT OF HEALTH; AND
9    REQUIRING CERTAIN HEALTH INSURANCE POLICIES TO COVER BLOOD
10    LEAD TESTS," FURTHER PROVIDING FOR TITLE OF ACT, FOR
11    LEGISLATIVE PURPOSE, FOR DEFINITIONS, FOR LEAD POISONING
12    PREVENTION, ASSESSMENT AND TESTING, FOR DUTIES OF DEPARTMENT
13    AND FOR BLOOD LEAD ASSESSMENT AND TESTING COVERAGE.
14    THE GENERAL ASSEMBLY OF THE COMMONWEALTH OF PENNSYLVANIA
15 HEREBY ENACTS AS FOLLOWS:
16    SECTION 1.   THE TITLE OF THE ACT OF NOVEMBER 3, 2022
17 (P.L.2135, NO.150), KNOWN AS THE CHILDHOOD BLOOD LEAD TEST ACT,
18 IS AMENDED TO READ:
19AN ACT
20 PROVIDING FOR BLOOD LEAD ASSESSMENT AND TESTING OF CERTAIN
21    CHILDREN AND PREGNANT WOMEN BY HEALTH CARE [PROVIDERS]
22    PRACTITIONERS; IMPOSING DUTIES ON THE DEPARTMENT OF HEALTH;
23    AND REQUIRING CERTAIN HEALTH INSURANCE POLICIES TO COVER
24    BLOOD LEAD TESTS.
25    SECTION 2.   SECTION 3(3) OF THE ACT IS AMENDED TO READ:
26 SECTION 3.   LEGISLATIVE PURPOSE.
27    THE PURPOSES OF THIS ACT ARE:
28* * *
29(3)   TO [ENCOURAGE] REQUIRE THE TESTING OF ALL CHILDREN
30    IN THIS COMMONWEALTH BY TWO YEARS OF AGE SO THAT PROMPT
31    DIAGNOSIS AND TREATMENT, AS WELL AS THE PREVENTION OF HARM,
32    ARE POSSIBLE.
33    SECTION 3.   SECTION 4 OF THE ACT IS AMENDED BY ADDING A
34 DEFINITION TO READ:
20250HB0916PN3286  - 9 -
1 SECTION 4.      DEFINITIONS.
2    THE FOLLOWING WORDS AND PHRASES WHEN USED IN THIS ACT SHALL
3 HAVE THE MEANINGS GIVEN TO THEM IN THIS SECTION UNLESS THE
4 CONTEXT CLEARLY INDICATES OTHERWISE:
5    * * *
6    "HEALTH CARE PRACTITIONER."  AS DEFINED IN SECTION 103 OF THE
7 ACT OF JULY 19, 1979 (P.L.130, NO.48), KNOWN AS THE HEALTH CARE
8 FACILITIES ACT.
9    * * *
10    SECTION 4.  SECTIONS 5, 6(A) AND (B)(2) AND 7(A) AND (B) OF
11 THE ACT ARE AMENDED TO READ:
12 SECTION 5.      LEAD POISONING PREVENTION, ASSESSMENT AND TESTING
13REQUIREMENTS.
14    [(A)    LEAD TESTING FOR CHILDREN.--
15(1)   THE FOLLOWING APPLY:
16(I)    A HEALTH CARE PROVIDER SHALL CONSIDER POSSIBLE
17LEAD EXPOSURE IN AN INDIVIDUAL PATIENT BY EVALUATING RISK
18FACTORS FOR LEAD EXPOSURE AND PERFORM BLOOD LEAD TESTING
19IN ACCORDANCE WITH RECOMMENDATIONS FROM THE CENTERS FOR
20DISEASE CONTROL AND PREVENTION AND THE AMERICAN ACADEMY
21OF PEDIATRICS BY 24 MONTHS OF AGE.
22(II)    IF A PATIENT HAS NEVER BEEN TESTED IN
23ACCORDANCE WITH RECOMMENDATIONS FROM THE CENTERS FOR
24DISEASE CONTROL AND PREVENTION AND THE AMERICAN ACADEMY
25OF PEDIATRICS BY 24 MONTHS OF AGE, A HEALTH CARE PROVIDER
26SHALL CONSIDER POSSIBLE LEAD EXPOSURE AND PERFORM BLOOD
27LEAD TESTING IN AN INDIVIDUAL PATIENT BETWEEN 24 MONTHS
28AND 72 MONTHS OF AGE.
29(III)    A HEALTH CARE PROVIDER SHALL MAKE REASONABLE
30EFFORTS TO ENSURE THAT A PATIENT'S PARENT OR LEGAL
20250HB0916PN3286  - 10 -
1GUARDIAN UNDERSTANDS THE RISKS AND BENEFITS OF BLOOD LEAD
2TESTING PRIOR TO OBTAINING CONSENT.
3(2)   IF A PATIENT'S PARENT OR LEGAL GUARDIAN CONSENTS TO
4    BLOOD LEAD TESTING FOR THE PATIENT UNDER PARAGRAPH (1) AND
5    THE RESULTS OF A CAPILLARY BLOOD LEAD TEST INDICATE AN
6    ELEVATED BLOOD LEAD LEVEL, THE HEALTH CARE PROVIDER SHALL
7    PERFORM A CONFIRMATORY BLOOD LEAD TEST BY VENIPUNCTURE WITHIN
8    12 WEEKS OF THE FIRST BLOOD LEAD TEST AFTER OBTAINING THE
9    CONSENT OF THE PATIENT'S PARENT OR LEGAL GUARDIAN.]
10    (A.1)    LEAD TESTING REQUIREMENTS FOR CHILDREN.--
11(1)   A HEALTH CARE PRACTITIONER SHALL MAKE REASONABLE
12    EFFORTS TO ENSURE THAT A PATIENT UNDER THE HEALTH CARE
13    PRACTITIONER'S CARE RECEIVES AT LEAST ONE BLOOD LEAD TEST BY
14    12 MONTHS OF AGE AND A SECOND BLOOD LEAD TEST BY 24 MONTHS OF
15    AGE.
16(2)   IF A PATIENT HAS NEVER BEEN TESTED BY 24 MONTHS OF
17    AGE, A HEALTH CARE PRACTITIONER SHALL ENSURE THAT THE PATIENT
18    RECEIVES AT LEAST ONE BLOOD LEAD TEST BETWEEN 24 MONTHS AND
19    72 MONTHS OF AGE.
20(3)   IF A CAPILLARY BLOOD LEAD TEST INDICATES AN ELEVATED
21    BLOOD LEAD LEVEL, A HEALTH CARE PRACTITIONER SHALL PERFORM A
22    CONFIRMATORY BLOOD LEAD TEST BY VENIPUNCTURE IN ACCORDANCE
23    WITH RECOMMENDATIONS FROM THE CENTERS FOR DISEASE CONTROL AND
24    PREVENTION.
25    (B)    LEAD EXPOSURE RISK ASSESSMENT AND TESTING REQUIREMENTS
26 FOR PREGNANT WOMEN.--A HEALTH CARE [PROVIDER] PRACTITIONER SHALL
27 CONSIDER POSSIBLE LEAD EXPOSURE IN INDIVIDUAL PREGNANT WOMEN BY
28 EVALUATING RISK FACTORS FOR LEAD EXPOSURE AND PERFORM BLOOD LEAD
29 TESTING IF A SINGLE RISK FACTOR IS IDENTIFIED IN ACCORDANCE WITH
30 RECOMMENDATIONS FROM THE CENTERS FOR DISEASE CONTROL AND
20250HB0916PN3286  - 11 -
1 PREVENTION AND THE AMERICAN COLLEGE OF OBSTETRICIANS AND
2 GYNECOLOGISTS.
3    (C)   REPORTING.--HEALTH CARE [PROVIDERS] PRACTITIONERS AND
4 LABORATORIES SHALL COMPLY WITH REPORTING REGULATIONS AS
5 SPECIFIED IN 28 PA. CODE § 27.34 (RELATING TO REPORTING CASES OF
6 LEAD POISONING).
7    (D)   COMMUNICATION OF RISKS AND BENEFITS.--NOTWITHSTANDING
8 SUBSECTION (E), A HEALTH CARE PRACTITIONER SHALL MAKE REASONABLE
9 EFFORTS TO ENSURE THAT A CHILD'S PARENT OR LEGAL GUARDIAN, OR A
10 WOMAN UNDER PRENATAL CARE, UNDERSTANDS THE BENEFITS AND RISKS OF
11 A BLOOD LEAD TEST.
12    (E)   NONAPPLICABILITY.--THE REQUIREMENTS UNDER THIS SECTION
13 SHALL NOT APPLY IF A CHILD'S PARENT OR LEGAL GUARDIAN, OR A
14 WOMAN UNDER PRENATAL CARE, OBJECTS TO THE BLOOD LEAD TEST FOR
15 ANY REASON. A HEALTH CARE PRACTITIONER SHALL DOCUMENT THE
16 OBJECTION IN WRITING AND INCLUDE THE OBJECTION IN THE PATIENT'S
17 MEDICAL RECORD. BEFORE PERFORMING A BLOOD LEAD TEST UNDER THIS
18 SECTION, THE HEALTH CARE PRACTITIONER SHALL NOTIFY THE CHILD'S
19 PARENT OR LEGAL GUARDIAN, OR THE WOMAN UNDER PRENATAL CARE, OF
20 THE OPTION TO OBJECT TO A BLOOD LEAD TEST.
21 SECTION 6.     DUTIES OF DEPARTMENT.
22    (A)   COMPREHENSIVE EDUCATIONAL PROGRAM.--THE DEPARTMENT SHALL
23 CONDUCT A PUBLIC INFORMATION CAMPAIGN TO INFORM PARENTS OF YOUNG
24 CHILDREN, PHYSICIANS, NURSES AND OTHER HEALTH CARE [PROVIDERS]
25 PRACTITIONERS OF THE LEAD ASSESSMENT AND TESTING REQUIREMENTS OF
26 THIS ACT.
27    (B)   DISTRIBUTION OF LITERATURE ABOUT CHILDHOOD LEAD
28 POISONING.--
29* * *
30(2)     EDUCATIONAL MATERIALS SHALL BE AVAILABLE AT NO COST
20250HB0916PN3286  - 12 -
1    AND SHALL BE DEVELOPED FOR SPECIFIC AUDIENCES, INCLUDING
2    HEALTH CARE [PROVIDERS] PRACTITIONERS, HOMEOWNERS, LANDLORDS
3    AND PARENTS OR CAREGIVERS.
4 SECTION 7.     BLOOD LEAD ASSESSMENT AND TESTING COVERAGE.
5    (A)   GENERAL RULE.--A HEALTH INSURANCE POLICY OR GOVERNMENT
6 PROGRAM COVERED UNDER THIS SECTION SHALL PROVIDE TO COVERED
7 INDIVIDUALS OR RECIPIENTS BLOOD LEAD TESTS AS FOLLOWS:
8(1)   IN THE CASE OF INDIVIDUALS OR RECIPIENTS WHO ARE
9    PREGNANT, ONE BLOOD LEAD TEST PER PREGNANCY [IF A SINGLE RISK
10    FACTOR IS IDENTIFIED IN ACCORDANCE WITH RECOMMENDATIONS FROM
11    THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE
12    AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS].
13(2)   IN THE CASE OF INDIVIDUALS OR RECIPIENTS WHO ARE:
14(I)    UNDER TWO YEARS OF AGE, AT LEAST [ONE BLOOD LEAD
15TEST] TWO BLOOD LEAD TESTS BY 24 MONTHS OF AGE IN
16ACCORDANCE WITH RECOMMENDATIONS FROM THE CENTERS FOR
17DISEASE CONTROL AND PREVENTION AND THE AMERICAN ACADEMY
18OF PEDIATRICS [AND, IF]; AND
19(II)   BETWEEN 24 MONTHS OF AGE AND 72 MONTHS OF AGE,
20AT LEAST ONE BLOOD LEAD TEST BY 72 MONTHS OF AGE IF THE
21INDIVIDUAL OR RECIPIENT HAS NEVER BEEN TESTED BY 24
22MONTHS OF AGE.
23(3)   IF THE RESULT OF THE BLOOD [LEVEL] LEAD TEST COVERED
24    UNDER PARAGRAPH (1) OR (2) INDICATES AN ELEVATED BLOOD LEAD
25    LEVEL, ANOTHER BLOOD LEAD TEST BY VENIPUNCTURE [WITHIN 12
26    WEEKS OF THE BLOOD LEVEL TEST IN WHICH THE ELEVATED BLOOD
27    LEAD LEVEL WAS INDICATED.] IN ACCORDANCE WITH RECOMMENDATIONS
28    FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION.
29    (B)   COPAYMENTS, DEDUCTIBLES AND COINSURANCE.--COVERAGE UNDER
30 THIS SECTION SHALL BE SUBJECT TO [COPAYMENT, DEDUCTIBLE AND
20250HB0916PN3286  - 13 -
1 COINSURANCE PROVISIONS AND ANY OTHER GENERAL EXCLUSIONS OR
2 LIMITATIONS OF A HEALTH INSURANCE POLICY OR GOVERNMENT PROGRAM
3 TO THE SAME EXTENT AS OTHER MEDICAL SERVICES COVERED BY THE
4 POLICY OR PROGRAM ARE SUBJECT TO THESE PROVISIONS.] THE TERMS
5 AND CONDITIONS OF THE APPLICABLE HEALTH INSURANCE POLICY.
6    * * *
7    SECTION 5.   THE AMENDMENT OF SECTION 7(A) AND (B) OF THE ACT
8 SHALL APPLY AS FOLLOWS:
9(1)    FOR HEALTH INSURANCE POLICIES FOR WHICH EITHER RATES
10    OR FORMS ARE REQUIRED TO BE FILED WITH THE INSURANCE
11    DEPARTMENT OR THE FEDERAL GOVERNMENT, THE AMENDMENT OF
12    SECTION 7 OF THE ACT SHALL APPLY TO ANY POLICY FOR WHICH A
13    FORM OR RATE IS FIRST FILED ON OR AFTER THE EFFECTIVE DATE OF
14    THIS SECTION.
15(2)    FOR HEALTH INSURANCE POLICIES FOR WHICH NEITHER
16    RATES NOR FORMS ARE REQUIRED TO BE FILED WITH THE INSURANCE
17    DEPARTMENT OR THE FEDERAL GOVERNMENT, THE AMENDMENT OF
18    SECTION 7 OF THE ACT SHALL APPLY TO ANY POLICY ISSUED OR
19    RENEWED ON OR AFTER 180 DAYS AFTER THE EFFECTIVE DATE OF THIS
20    SECTION.
21    SECTION 6.   THIS ACT SHALL TAKE EFFECT IN 60 DAYS.
20250HB0916PN3286  - 14 -